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Summary: Liver disease is associated with profound and characteristic changes in lipoprotein composition and
metabolism. The most pronounced alterations are the Formation of lipoprotein-X in intra- and extrahepatic
cholestasis, the decrease of apolipoproteins A-I and A-II and the increase of apolipoprotein E. These
alterations impair the activities of both lipoprotein lipase and lecithin : cholesterol acyltransferase. They are
also responsible for an abnormal receptor mediated uptake of the lipoproteins from plasma. The abnormal
lipid and apolipoprotein composition of the lipoproteins in liver disease %appears to affect various important
functions of cell membranes. The understanding of how these changes occur and their significance in the
pathogenesis of other metabolic disturbances secondary to the abnormal lipid metabolism are important
challenges for future research.
Introduction
Lipids serve both äs a major energy source and äs
structural components of cell membranes. Not
surprisingly, their homeostasis is carefully maintained
by a number of iiiterrelated metabolic pathways, not
only of the lipids but also of the carbohydrates and
proteins. The insolubility of lipids in aqueous fluids
adds complexity to the transport processes in plasma
by creating a need for a carrier System. Tttis carrier
System of protein-lipid aggregates or lipoproteins has
been the subject of intense investigation for many
years. The basic achievements of the last three de-
cades, which have led tö ä better understanding of
the biochemistry and pathobiochemistry of lipids in
health and disease, arose from the characterization
of the lipoprotein System in terms of the structural
properties and metabolism of the plasma lipopro*
teins.
The association between plasma lipid concentrations
and cardiovascular risk was withoüt doubt the major
Stimulus in clinical research on plasma lipidis. How-
ever, lipid disturbances ocourring in liver disease and
in particülar the hypercholesterolaemia accompany-
ing biliary obstruction, a phenomeiion recorded first
by Flint (1) over a Century ago, are among the oldest
lipid disorders known to clinical medicine.
The data discussed in this review are intended to
demonstrate that liver dysfunction produces complex
derangements of the lipoprotein System. The basic
defects seem to be a disturbed hepatic biosynthesis
of lipoproteins, a disturbed hepatic removal of lipo-
proteins from the circulation and a disturbed plasma
lipolytic activity.
Nature of Lipoproteins in Plasma
The liver plays a central role in the regulation of
lipoprotein synthesis and degradation äs well äs in
the storage of lipids in various tissues. Therefore,
liver dysfunction can be associated with hyper-,
hypo-, dys- or paralipoproteinaemia. Any approach
to an appreciation of the pathobiochemical signifi-
cance of the various normal and abnormal plasma
lipoprotein patterns requires a consideratioü of the
multifaetorial control mechanisms regulating the li-
poprotein system.
Lipoprotein metabolism covers a broad field and
cannot be fully suminarized in a review such äs this
(for further Information see 1. c. (2, 3)).
Important terms and Steps in lipoprotein metabolism
can be summarized äs follows:
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— intestinal absorption of lipids;
— rates of synthesis of lipids and apolipoproteins;
— assembly and secretion of lipoproteins;
— structure of lipoproteins and apolipoproteins;
— interconversion and intravascular catabolism of
lipoproteins mediated by plasraa-lipases and leci-
thin: cholesterol acyltransferase;
— recognition, uptake and catabolism of lipoprote-
ins by hepatic and extrahepatic cells;
— transformation and elimination of lipids and ste-
roids by the liver.
The plasma lipoproteins are water-soluble macromo-
lecular complexes heterogenous in size and composi-
tion, with relative molecular weights of up to several
million and a particle sizes in the ränge 7 — 1000 nm
(see fig. 1). They contain specific proteins, apolipo-
proteins and lipids. All plasma lipoproteins possess
a common struetural Organisation that is charao
terized by a hydrophobic core composed of choleste-
rol esters and triglycerides surrounded by a relatively
hydrophilic shell cönsisting of rproteins, phpspholip-
ids and most of the unesterified cholesterol. The most
commonly adapted elassification of plasma lipoprote-
ins is based on tfaeir behaviour in the ultracentrifuge
in high salt Solutions (4, 5) (see flg. 2). According to
their flotation characteristics the lipoproteins have
been classified äs very low density lipoproteins
(VLDL), low density lipoproteins (LDL) and high
density lipoproteins (HOL). All three major density
Chylonnicron VLDL
LDL HOL
Fig. l . Electron microscopy of the four major lipoprotein fractions (chylomicrons, VLDL, LDL and HE>L). Negative staining
with 1% potassium Dhosohotunffstate.
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Human plasma lipoproteins
Density kg/l
VLDL LDL HOL
0.9 1.006 1.063 1.21
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Fig. 2. Scheine for the Separation of plasma lipoproteins by
ultracentrifugation, protein lipid composition of iso-
lated fractions and electrophoretic mobility of the four
major lipoprotein fractions. Quantification can best be
achieved by quantitative lipoprotein electrophoresis (8).
Prot. = protein; PL = phospholipids; Chol. = cho-
lesterol; TG = triacylglycerols.
fractions exhibit varying degfees of heterogeneity and
differences in size and protein lipid composition. The
lipoproteins can also be separated by electrophoretic
methods in various supporting media (6, 7). Accord^
ing to their electrophoretic migration they are classi-
fied äs pre-ß- (VLDL), ß- (LDL) and a-Jipoproteins
(HDL). Chylomicrons remain at the origin. In recent
years a number of other techniques have been used
for separating lipoproteins according to their phys-
ico-chemical properties, such äs gel filtration, size
exclusion high performance liquid chromatography,
adsorptiön chromatography, heparin-sepharose af-
finity chromatography, immuno-absorption chroma^
tography, polyacrylamide gel electrophoresis* isota-
chophoresis, isoelectrofocussing and various other
techniques.
Some of the Separation and classification Systems
have proven to be of value in establishing a relation-
ship between lipoprotein profiles and various dis-
eases. However, for practical purpose, Isolation, char-
acterization and measurement of plasma lipoproteins
are most widely based on their electrophoretic mobil-
ity or hydrated density. Results obtained from both
techniques are often used interchangeably, which may
be unjustified, especially if abnormal lipoproteins oc-
cur äs a result of metabolic disturbances. This is
because the lipoproteins represent dynamic structures
in plasma, which are subject to exchange and transfer
processes äs well äs remodelling during their metab-
olism in the vascular space.
The Apolipoproteins and Lipolytic Enzymes
Various groups of proteins are important regulators
of the lipoprotein System. These include the apolipo-
proteins, transport and transfer proteins, enzymes
involved in lipoprotein metabolism and lipoprotein
receptors.
Apolipoproteins are important structural constitu-
ents of the lipoprotein particles and have been shown
to participate in Jipoprotein synthesis, secretion, pro-
cessing and catabolism. In the last 15 years advances
in techniques of protein chemistry have allowed the
identification, isolation and characterization of al-
most a dozen distinct apolipoproteins (see tab. 1).
Protein sequencing techniques have allowed the as-
signment of the primary amino acid sequence of six
of these proteins. Recently c-DNA and genomic
clones have been derived for several of these apolipo-
proteins. The DNA sequences combined with cell-
free synthesis and tissue and organ culture studies
have revealed the presence of apolipoprotein precur-
sors, including prepeptides and in some cases propep-
tides. In addition most of the apolipoprotein genes
have been mapped in the human genome. Finally
human mutations in the apolipoprotein genes have
been identified at both the amino acid and DNA-
level (for further detailed Information see 1. c. (9,10)).
The impörtaiice of the apolipoproteins for maintain-
ing the structural properties of the plasma lipopro-
teins and their functional roles in lipoprotein metab-
olism (some fünction äs activators or inhibitors of
lipolytic enzymes) and clearance from the plasma
(some operate äs ligands for specific transport recep-
tors) show that the determination of their concentra-
tion and distribution may be of importance for a
better understanding of the pathobiochemistry of li-
pid disturbances, mainly in secondary forms of dysli-
poproteinaemia such äs in liver disease.
Of the four major plasma-lipases involved in lipopro-
tein metabolism (lecithin:cholesterol-acyl-transferase
(LCAT), lipoprotein lipase, hepatic triglyceride li-
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Tab. 1. Characlerization and function of human apolipoproteins.
Apolipo-
protein
A I
Al l
A IV
B-100
B-48
C I
CII
C IIIo.2
D
E2^
F
G
H
Approximate
relative
molecular
mass
28000
18000
45000
514000
250000
6500
9000
9000
22000
34000
30000
75000
45000
Major density
class
HDL
HDL, Chylomicrons
Chylomicrons
VLDL-IDL-LDL
Chylomicrons-VLDL-HDL
Chylomicrons-VLDL-HDL
Chylomicrons-VLDL-HDL
Chylomicrons-VLDL-HDL
HDL
Chylomicrons-VLDL-HDL
HDL
VHDL
Chylomicrons
Major sites of
synthesis in man
liver-intestine
iiver-intestine
intestine
liver
intestine-liver
liver
liver
liver
?
liver, macrophage
?
7
?
Major function in lipoprotein
metabolism*)
activates LCAT, struetural
structural ' f
activates LCAT
binds to LDL receptor, structural
stfuctural
activates LGAT
activates lipoprotein lipase
inhibits lipoprotein uptake by the liver
cholesteryl ester exchange protein
binds to E receptor
—
-
—
(a) 250000
determinant 700 000 HDL, Chylomicrons ? (liver-intestine)
*) LCAT = lecithin : cholesterol acyltransferase
pase, and the phospholipases), three are synthesized
in the liver, i. e. lecithin : cholesterol-acyl-transferase,
hepatic triglyceride lipase and phospholipase.. Other
important cellular enzymes involved in lipid metab-
olism, such äs acyl-CoA: cholesteryl-acyl-transferase
(ACAT), hydroxymethylglutaryl-CoA-reductase, hy-
droxymethylglutaryl-CoA-synthase, cholesterol-est-
er-hydrolase, enzymes of fatty acid and phosphölipid
synthesis and cholesterol 7-a hydrolase are also he-
patic enzymes.
The Metabolism of Lipoproteins in Plasma
Although it has been assumed for many years that
the terminal catabolism of mammalian plasma lipo-
proteins occurs predominantly in the liver, most de-
tailed investigations of receptor mediated processing
of macromolecules in this organ have until recently
not been concerned with plasma lipoproteins, but
rather with other plasma proteins, polypeptides and
hormones. The first detailed studies on receptor medi-
ated endocytosis of lipoproteins in the liver were
facilitated by the discovery that administration of
pharmacological amounts of öestradiol to rats in*
duces a several fold increase in the number of LDL-
receptors on the surface of hepatocytes and increases
the uptake and catabolism of LDL by the liver (11).
From combined biochemical and morphological ap-
proaches it was possible to show that the various'
steps to lipoprotein binding to receptors, intemalisa-
tiön, movement to the lysosomal regiön and lysoso-
mal processing resemble clösely those described for
LDL in fibroblasts (12,13) and other macromolecules
in hepatocytes (see fig. 3). Cholesterol taken up by
hepatocytes suppresses hydroxymethylglutaryl-CoA^
reductase, activates acyl CoA: cholesteryl acyl-
transferase, inhibits expression of LDL receptors but
leaves apolipoproteiri E receptor activity unchanged
(14, 15). LDL binds to the receptor via a single site
on apolipoprotein B. Also VLDL remnants bind to
this receptor but with much higher affinity than that
of LDL, presumably because these particles possess
apolipoprotein E and bind polyvalently to the LDL-
receptor. These differences in affinity have major
Apolipoprotein E
receptor
(Chylomicron
remnants)
Apolipoprotein
B100:E
receptor
(IDL,VLDL
änd LDL)
1. HMG CoA reductase f
2. ACAT ' *
3. LDL Teqeptqr f
4. Remnaht receptor —
Free
cholesterol
o°0°
Lysosöme Aminoacids
Fig. 3. Scheine for lipoprotein uptake and metabolism by hepa-
tocytes (for detail see text).
HMGCoA = 3-hydroxy-3-methyiglutaryl-CoA
ACAT = acyl^CoAicholesteryl acyltransferase
ER = endoplasinatic reticultim
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consequences for lipoprotein catabolism, since VLDL
remnants are removed from the blood within minutes,
whereas LDL circulates for many hours (16, 17).
Since it has been estimated that the liver clears more
than 80% of the structural lipids, phospholipids and
cholesterol from the circulation (18) it is important
to realize that more than one receptor seems to par-
ticipate in hepatic lipoprotein catabolism and that
processes other than receptor mediated endocytosis
may also participate in hepatic lipoprotein metab-
olism. Studies in a mutant rabbit that lacks LDL-
receptors (Watanabe hereditary hyperlipidaemic,
WHHL, rabbit) have provided evidence that LDL-
receptors are not necessary for uptake of chylomicron
remnants by the liver (19). Uptake of chylomicrons
by hepatic parenchymal cells in these animals seems
to occur via a distinct chylomicron remnant receptor,
the apolipoprotein E receptor, which so far has only
been described for hepatocytes. A third lipoprotein
receptor, the Scavenger receptor (Scavenger-system),
present mainly in reticulo-endothelial cells and also
in Kupffer-cells, efficiently removes certain chemically
modified and abnormal lipoproteins from the blood
(10, 21). The importance of this pathway for lipopro-
tein catabolism is uncertain because the extent to
which lipoproteins are modified in vivo so äs to
permit them to be recognized by the Scavenger recep-
tor is still unknown. On the other hand, LDL and
possibly also VLDL remnants are also taken up by
hepatocytes of WHHL-rabbits, which may indicate
the existence of other, äs yet undefined processes
capable of Clearing these lipoproteins from the circu-
lation (22). Also binding sites for high density lipo-
proteins (HOL) have been postulated for hepatocytes
and demonstrated in membrane preparations of rat
liver (23). This process however, may not involve
endocytosis, because the rates of uptake of lipids and
the apolipoproteins by this System are different.
The role of the liver in the synthesis of apolipoproter
ins and lipids, their assembly in the Gö/£/-apparatüs
and the secretion of lipoproteins was established in
the late 50's and then became the focus of a great
deal of research (for definition see 1. c. (24)). It was
appreciated that the rate of synthesis .and secretion
of these particles by the liver is an important determi^
nant of their circulating levej. Secretion and degrada-
tion are equally important in detennining lipoprotein
levels because in the steady state the rate of synthesis
must equal the rate of degradatipn, and a change in
either will cause a change in the circulating level.
The role of the liver in the regulation of the plasma
lipoprotein System can briefly by outlined äs follows
(see fig. 4):
The liver secretes two types of nascent lipoproteins:
nascent VLDL which is rieh in triglycerides and apoli-
poprotein B but contains very little apolipoprotein C
and apolipoprotein E, and nascent HDL which is
rieh in phospholipids, unesterified cholesterol, apoli-
poprotein E and apolipoprotein A-II and contains
some apolipoprotein C. These particles possess lami-
nar structures and are found within the density class d
l .063 — l .21 kg/l on ultracentrifugation. After nascent
HDL particles enter the plasma they are acted upon
by lecithin : cholesterol acyltransferase, an enzyme
also synthesized and secreted by the liver. Cholesterol
is esterified, thus rendering it hydrophobic, and it is
thereby transferred into the core of the particles. This
brings about a change in the shape of the particles
into a globular form. At the same time there is an
exchange of apolipoprotein E and apolipoprotein C
with apolipoprotein A-I, the cofactor for lecithin:
cholesterol acyltransferase which is primarily derived
from the intestine. By this mechanism mature HDL
is generated, and it is believed that these particles
leave the circulation by an uptake mechanism in
the liver, which* however, has not yet been fully
elucidated. During the esterification of HDL-cho-
lesterol, apolipoprotein C and apparently apolipo-
protein E is transferred to the pathway leading from
nascent to mature VLDL, intermediate-density lipo-
proteins (IDL) and finally to LDL. This metabolic
cascade is regulated by lipoprotein lipase and by
hepatic-triglyceride-hydrolase, the two major en-
zymes of postheparin plasma lipolytic activity. Dur-
ing triglyceride hydrolysis some apolipoprotein C and
apolipoprotein E is transferred back to the HDL
density class. It has been postulated that these apo-
lipoproteins form, together with apolipoprotein A-I,
apolipoprotein D, lipid transfer proteins and lecithin:
cholesterol acyltransferase, the so-called Reversed
CholesteroJ Transport Complex (RCTC), by which
cholesterol is transferred from the peripheral cells to
the liver for excretion.
The Abnormal Lipoprotein Profile in Liver Disease
From the complex metabolic pathways of the plasma
lipoproteins in which the liver is predominately in-
volved it is clear that abnormal liver function may
cause profoünd disturbances in the lipoprotein sys-
tem. The abnormal patterns, however, are generally
not indicative of a particular liver disease. Therefore
in the following descripüon emphasis will be placed
on the pathöbiochemical aspects, rather than at-
tempting to directly link a particular lipoprotein or
lipid pattern to a specific liver dysfunction.
J. Clin. Chem. Ciin. Biochem./Vol. 25,1987/No. 9
546 Seidel: Lipoproteins in liver disease
30% extra-
hepatic T G
Fig. 4. Scheme to illustrate the metabolism of plasma lipoproteins in human plasma (for detail see text).
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triacylglycerols (TG)
esterified cholesterol (EC)
unesterified cholesterol (UC)
phospholipids (PL)
free fatty acids (FFA)
lipoprotein lipase (LPL)
hepatic triacylglycerol hydrplase (H-TGL)
lecithin : cholesterol acyltransferase (LCAT)
The following abnormalities in plasma lipids, lipopro-
teins and apolipoproteins may occur äs a result of
liver dysfunction:
— hypercholesterolaemia;
— increased ratio of free to esterified cholesterol;
— hyperphospholipidaemia;
— normal or eleväted levels of plasma triglycerides;
- increased or decreased concentration of LDL;
— normal or eleväted levels of VLDL, often with
abnormal (ß-) mobility on electrophoresis;
— normal or decreased levels of HDL with a marked
heterogeneity and abnormal composition of HDL
particles;
— decreased concentrations of apolipoproteins A
and B-100;
— eleväted concentration of apolipoprotein E;
— increased concentrations of IDL and apolipopro-
tein B-48;
— decreased plasma post-heparin lipolytic activity;
— eleväted or reduced activity of lecithin: chole-
sterol acyltransferase;
— appearance of the abnormal lipoprotein-X (LP-
X) in cholestasis.
Electrophoresis of lipoproteins in liver disease reveals
a typicäl pattern of only one, often broadened, band
in the ß-position, which masks a heterogeneity which
can only be elucidated by the employment of various
analyticäl techniques (25). Drastic changes in the
concentration of apolipoproteins. often occur con-
comitantly with this lipoprotein pattern, but they are
not disease-specific (26, 27). The normalization of
these chatnges, höwever, may be helpful in following
the course of the disease.
• >
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Cholestasis and Hypercholesterolaemia
Several years ago we were able to show that the
lipoprotein pattern of cholestasis is mainly charac-
terized by the appearance of an abnormal lipoprotein
particle in the LDL density olass. This particle has
been subsequently isolated and characterized with
respect to its physicochemical properties. It has been
designated lipoprotein-X (28, 29). Lipoprotein-X has
the characteristics of a vesicle, in which a phospholi-
pid-cholesterol-apolipoprotein membrane structure
separates an internal from an external water compart-
ment. Its mean diameter is approximately 50 — 70 nm.
The disc-formation seen on electron micrographs is
not unique for this particle (30). Similar laminar
structures have been described for artificial lipid-
protein complexes; they have also been demonstrated
in the plasma of cholesterol-fed animals, äs well äs
in the plasma of patients with lecithin: cholesterol
acyltransferase deficiency (31, 32).
The protein-lipid compositioii of lipoprotein-X is un-
ique, and is characterized by a high content of phos-
pholipids and a low content of cholesterol esters (28).
Bile salts are bound to lipoprotein-X and, depending
on their concentration, may exert a strong infruence
äs a detergent on the physicochemical properties of
the particle (33). Albumin accounts for up to 60%
of the protein component of lipoprotein-X and is
primarily located inside the vesicle (29). In cöntrast,
the specific apolipoproteins of lipoprotein-X (apoli-
poprotein C and apolipoprotein D) are located on
the surface. Apolipoprotein B, the major apolipopro-
tein of LDL and also apolipoprotein E are not present
in lipoprotein-X. In addition, aggregates of various
liver and bile enzymes, such äs alkaline phosphatase
or -glutamyltransferase with lipoprotein-X have
been described, but have been erroneously interpreted
äs isoenzymes (34, 35, 36). The detection of lipopro-
tein-X in the serum pf a patient is the most sensitive
and specific clinical chemical parameter for the diag-
nostic confirmation or exclusion of cholestasis, äs
shown by a large nümber of clinical studies (for
further Information see L c. (37)).
The appearance of lipoprotein-X iii plasma has been
noted aftertbile duct Jigation in experimental labora-
tory animals and after insertion of the common bile
duct into the venous System (38).
In addition, incubation of bile lipoproteins with
serum leads to a complete conversion of the bile lipids
into lipoprotein-X (33). The data from both the in
vitro and in vivo experiments indicate that the bile
lipids are converted into lipoprotein-X when they
enter the plasma compartment, äs in cholestasis. The
finding that lipoprotein-X or its precursors are
formed in experiments in which only biliary lipids
and albumin are incubated together is of particular
theoretical and pathobiochemical significance. Such
precursors exhibit a high affmity for apolipoprotein
C and apolipoprotein D, which in the vascular space
may bring about disturbances in the balance or ex-
change of these apolipoproteins between VLDL and
HDL (see fig. 4), a mechanism which is important
for plasma lipoprotein metabolism. The hypertrigly-
ceridaemia of cholestasis may be caused by such a
mechanism, a view which is supported by the observa-
tion that these apolipoproteins are either absent or
drastically reduced in VLDL particles obtained from
patients with cholestasis (25, 27).
Results from Wallt et al. in our laboratory (39) con-
cerning the catabolism of lipoprotein-X, revealed that
lipoprotein-X is like other macromolecules taken up
and catabolized by the reticuloendothelial System,
primarily by the spieen and not äs most normal
plasma lipoproteins by the liver. Moreover receptor-
binding studies iijdicate that isolated hepatocytes or
fibroblasts exhibit a low degree of binding and uptake
of lipoprotein-X, whereas in lymphocytes high rates
are observed and these cell types show a marked
reduction in the activity of the hydroxymethylgluta-
ryl-CoA-reductase when in contact with lipoprotein-
X. Also, the reductase activity is greatly depressed in
lymphocytes from cholestatic patients.
Normally chylomicron remnants are rapidly removed
from the circulation by the liver and are most effective
in suppressing hepatic cholesterolgenesis. Lipopro-
tein-X causes a marked Inhibition of remnant uptake
by isolated perfused livers and isolated hepatocytes,
even though it is devoid of apolipoprotein B and
apolipoprotein E and is not taken up by hepatocytes
itself (14, 39).
A parallel clinical finding is hypertriglyceridaemia
with persisting apolipoprotein B-48, which is often
noted in cholestatic patients and is indicative of the
accumulation of remnant-like particles (40). In cön-
trast to the direct effects of lipoprotein-X on chylomi-
cron remnant uptake, no such effects of lipoprotein-
X on the degradation of LDL by isolated perfused
livers or monolayer cultures of skin fibroblasts are
noted (l 5, 39).
In order to understand the relevance of these in vitro
results for the Situation in vivo, we perfused livers
from cholestatic rats which had lipoprotein-X in their
serum. Such livers degraded twice äs much [125I]LDL
äs normal livers. A similar Situation is observed in
patients with cholestasis. The apolipoprotein B con-
centration in the serum of cholestatic patients is re-
J. Clin. Chem. Clin. Biochem. / Vol. 25,1987 / No. 9
548 Seidel: Lipoproteins in liver disease
duced to half ofthat found in normal subjects, reflect-
ing a reduced LDL concentration. Also, in the iso-
lated perfused liver lipoprotein-X stimulates the key
enzyme of cholesterol synthesis, hydroxymethylglut-
aryl-CoA-reductase, by a factor of 2.5 (14, 39). Taken
together, these observations are of particular interest
with respect to both hepatic lipoprotein receptor ac-
tivity and cholesterolgenesis in hepatocytes. Although
lipoprotein-X is devoid of apolipoprotein B and apo-
lipoprotein E, it appears to affect apolipoprotein E
receptors directly, but hepatic LDL receptor activity
indirectly. The mechanism by which lipoprotein-X
affects the function of the hepatic apolipoprotein E
receptor is äs yet unknown but presents an important
challenge for future research in this field.
intake of alcohol (45, 46) seems to be caused by an
accelerated turn-over of very low density lipopro-
teins. Nikkilä et al. (47) found both the fractional
catabolic rate of VLDL and the turn-over rate of
VLDL to be high in alcoholic men, and they normal-
ized following two weeks of abstinence. However, the
removal of triglycerides from plasma is not increased
by acute alcohol intake but rather impaired. Contin-
ued use causes a gradual return to normal concentra-
tions of VLDL. This change parallele an increase in
lipoprotein lipase activity (47). The reason for the
decrease of plasma LDL concentration follöwiiig
heavy alcohol consumption rernains to be elucidated
(46). Both elevated HDL and reduced LDL return
rapidly to normal after alcohol withdrawal.
Hypertriglyceridaemia
Clinical studies first indicated that hypertriglycerid-
aemia is also frequently found in severe cholestasis
and in primary biliary cirrhosis (41, 42).
The main increase in triglycerides is found in the
LDL-II density class. Triglyceride-rich, cholesterol-
poor apolipoprotein B, apolipoprotein C and apoli-
poprotein E-containing intermediate density lipopro-
teins account for the accumulation of tryglycerides
in this density fraction (43). These unusual particles
are heterogeneous in size, ranging from 30 nm to 80
nm, and are thus much larger than normal LDL
(20 — 25 nm). Dietary studies have indicated that
these particles are remnants derived from a disturbed
catabolism of chylomicrons (25). Their accumulation
may be caused by reduced plasma lipolytic activity
and/or by a disturbed hepatic uptake due to an Inhibi-
tion of the apolipoprotein E receptor. Jahn et al.
recently demonstrated a decreased activity of hepatic
lipase in all his patients with primary biliary cirrhosis
due to the presence of a heat labile enzyme Inhibitor
(44). In contrast, altered cholesterol esterification was
only observed in subjects with advanced disease.
Influence of Alcohol Intake on the Lipoprotein System
Hypertriglyceridaemia äs a consequence of liver da-
mage by alcohol is also well known, but not fully
understood. The metabolic Situation is complicated,
äs acute and chronic intake of alcohol may bring
about opposing disturbances in lipid metabolism.
Moreover the quaritity of alcohol consumed is impor-
tant.The well-documented increase in plasma HDL
concentration following a constant, but non-toxice
HDL and a-Lipoproteins
The HDL fraction in liver disease contains hardly
any cholesterol esters or triglycerides, while the con^
centration of free cholesterol and phospholipids is
increased. The -lipoproteins cannöt be visualized on
lipoprotein electropherograms (25, 27). Ultracentrifu-
gal and Chromatographie analysis, höwever, reveal
the presence of lipoproteins in this density class but
with an unusual degree of heterogeneity. Ünder the
electron microscope most particles show rouleaüx
förmatiön similar to lipoprotein-X or nascent HDL
particles. The rates of apolipoprotein A-I catabolism
and elimination are increased by 2—4 föld in acute
alcohol hepatitis, äs compared with healthy contföl
subjects (48). From this observation i t may be con-
cluded that the diminished plasma concentration of
apolipoprotein A found in liver patients is primarily
due to its accelerated catabolism, rather than to ä
disturbed synthesis, äs described for Tangier disease,
a primary deficiency of HDL (49). The apolipopro-
tein A-I and apolipoprotein A-II in the plasma of
patients with liver disease often show a complete
dissociation and they lose much of their lipid binding
capacity (25). It is possible that the dissociation of
the two apolipoprotein A sübünits is a inajor reason
for their accelerated catabolism and this may well
result from a disturbed generation of mature HDL
from nascent HDL in the plasma of such patients,
emphasizing the general importanee of the structural
properties of a lipoprotein with respect to its metab-
olism. The HDL fraction in most patients with liver
disease not only shows decreased .concentrations of
their major apolipoprotein constituents, apolipopro-
tein A-I and apolipoprotein A-II, but also a marked
increase in apolipoprotein E (50), a phenomenön
which has also been described for familial leci-
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thin: cholesterol acyltransferase deficiency when
such patients are subject to a dietary cholesterol load.
Recently Owen et al. (51) reported that a subfraction
of HDL, containing primarily applipoprotein E,
strongly reduced LDL binding, internalization and
degradation in cultured human skin fibroblasts. In
contrast to normal HDL, these HDL particles were
also taken up and degraded by the fibroblasts appar-
ently through the LDL-receptor pathway. The parti-
cles also stimulated cellular cholesterol esterification,
increased cellular cholesterol ester content and sup-
pressed cholesterol synthesis and receptor activity
(51). It was concluded from these results that this
particulate HDL may deliver cholesterol to the cells
via LDL-receptor mediated uptake. It should be in-
teresting to elucidate whether in cirrhotic patients.
It is reasonable to anticipate that apolipoprotein E
accumulates in the HDL fraction äs a consequence
of plasma lecithin : cholesterol-acyl-transferase defi-
ciency.
In collaboration with Dr. Clemens from the Univer-
sity of Tübingen, Drs. Armstrong and Wallt from
our laboratory were able to demonstrate lipoproteins
with abnormal binding characteristics to lipoprotein
receptors in all three major density classes of a patient
suffering from familial lecithin: cholesterol acyl-
transferase deficiency. An abnormal HDL rieh in
apolipoprotein E with high affinity to heparin-sepha-
rose revealed a high binding affinity to the LDL
receptor in cultured fibroblasts, while a small sized
LDL from this patient showed a lower than normal
affinity to the LDL-receptor (52). In isolated perfused
rat livers the HDL fraction rieh in apolipoprotein E
was degraded more rapidly than any other lipopro-
tein isolated from the plasma of the patient.
The data discussed in this review indicate that liver
dysfunction produces complex derangements of the
lipoprotein System, The basic defects seeni to be a
disturbed hepatic biosynthesis of lipoproteins, a dis-
turbed hepatic removal of lipoproteins from the circu·*
lation and a disturbed plasma lipplytic activity. This
Suggestion is strongly supported by the finding of
struetural similärities betweeii naseent VLDL and
nascent HDL with the plasma VLDL and HDL accu-
mulating in liver disease patients.
Plasma .Lipoproteins and Plasma Membranes
We have described and discussed some of the most
! common abnormalities of lipoproteins, apolipopro-
teins and lipoly tic enzymes, disturbances of metabolic
regulation and altered lipoprotein-receptor activities
found in liver disease. Since most plasma lipopro-
teins, normal or abnormal, interact with cell surface
membranes and since cell membrane fluidity is known
to alter the capacity of cells for many important
biological mechanisms, it is reasonable to anticipate
that alterations of the lipoprotein System in liver
disease may have important consequences for a num-
ber of cellular functions including carrier mediated
transport, the properties of certain membrane-bound
enzymes, the binding to specific receptors, endo-
cytosis, depolarization dependent exocytosis, immu-
nological cytotoxicity, prostaglandin production, cell
growth and possibly for many other äs yet unknown
cell functions (53, 54). The effects of lipid modifica-
tion and cellular function were, however, very com-
plex. They often vary from one type of cell to another
and they do not exert a uniform effect on all processes
in a single cell line. Therefore, it is not yet possible
to make any generalizations or to predict how a given
cell System may respond to a particular type of lipid
modification. Many of the functional responses prob-
ably are caused dlrectly by the changes in membrane
lipid structure which affect either bulk lipid fluidity
or specific lipid domains. The confonnation or qua-
ternary structures of certain transport proteins, recep-
tors or enzymes probably are sensitive to changes in
the structure of their lipid microenvironement. This
may lead to changes in their biological activity. The
dynamic state of lipids in membrane bilayers was first
described by Singer & Nicolson in 1972 (55) äs one
of the fundamental factors of the fluid mosaic model
of membrane structure. The basic question to be
raised now is whether and to what extent the interac-
tion or exchange of membrane lipids with abnormal
lipoproteins in liver disease can modulate cell mem-
brane composition and consequently the activity of
membrane proteins. The immediate change in the
shape of red blood cells by incubation with lipoprote-
ins from liver disease patients (56), and the abnormal
erythrocytes (57, 58) and abnormal platelet aggrega-
. tion in human liver disease (59) indicate that it may
be possible to investigate this problem. Also the Inhi-
bition of hepatic apolipoprotein E receptor (14, 15,
39) by lipoprotein-X which is devoid of the protein
ligand to the receptor (29) may be a consequence of
an altered cell membrane fluidity deriving from the
interaction with lipoprotein-X. The hyperglycaemia
of liver disease may be another example of such a
general pathobiochemical mechanism.
It now seems important and interesting to further
correlate abnormal functions of organs and cells with
the abnormal composition of plasma lipoproteins in
liver disease.
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